Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kerry Anne Rogers"'
Autor:
Kerry Anne Rogers, Pearlly Yan, Ian W. Flinn, Deborah M. Stephens, Thomas J. Kipps, Sarah M. Larson, Laura Martz, Xi Chen, Huabao Wang, Ethan Hopping, Ralf Bundschuh, Alexandra Acosta, Daniela Baldoni, Anwesha Chaudhury, Jeanne Whalen, Nadia B. Hassounah, Nina Orwitz, Janghee Woo, John C. Byrd
Publikováno v:
Cancer Research, vol 83, iss 8_Supplement
Introduction VAY736 is an afucosylated, human monoclonal antibody engineered to enhance antibody-dependent cellular cytotoxicity that targets BAFF-R+ B cells for elimination. In preclinical CLL models, VAY736 showed antileukemic activity and, when co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b058004b09c48b907cbfd85a4f211f3
https://escholarship.org/uc/item/7hp9q9d7
https://escholarship.org/uc/item/7hp9q9d7
Autor:
Kerry Anne Rogers, Ying Huang, Lynne Abruzzo, Seema Ali Bhat, Tzyy-Jye Doong, Adam Kittai, Arletta Lozanski, Gerard Lozanski, Margaret Lucas, Kami J. Maddocks, Charelen Mao, Megan Nussbaum, Ellen J Sass, Swetha Suresh, John C. Byrd, Jennifer Ann Woyach
Publikováno v:
Journal of Clinical Oncology. 40:7540-7540
7540 Background: Targeted agent combinations for chronic lymphocytic leukemia (CLL) have resulted in safe regimens with improved progression-free survival (PFS) compared to chemoimmunotherapy. The optimal regimen and long-term outcomes remain unknown